428 related articles for article (PubMed ID: 25431951)
1. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
2. The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
Shen Y; Shi X; Pan J
PLoS One; 2013; 8(8):e73059. PubMed ID: 24009732
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
6. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
7. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
8. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract][Full Text] [Related]
9. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
10. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
Jin Y; Chen Q; Lu Z; Chen B; Pan J
Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
[TBL] [Abstract][Full Text] [Related]
11. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Cools J; Stover EH; Boulton CL; Gotlib J; Legare RD; Amaral SM; Curley DP; Duclos N; Rowan R; Kutok JL; Lee BH; Williams IR; Coutre SE; Stone RM; DeAngelo DJ; Marynen P; Manley PW; Meyer T; Fabbro D; Neuberg D; Weisberg E; Griffin JD; Gilliland DG
Cancer Cell; 2003 May; 3(5):459-69. PubMed ID: 12781364
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
[TBL] [Abstract][Full Text] [Related]
13. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
14. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
[TBL] [Abstract][Full Text] [Related]
15. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
17. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
18. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
19. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
